BioSpace News Archive

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 103,000 shares of KalVista common stock on October 2, 2023 as inducements material to each employee entering into employment with KalVista.

BioBam, the leading bioinformatics software company, is pleased to announce OmicsBox 3.1, its latest version packed with innovative features designed to empower researchers, scientists, and bioinformaticians in their pursuit of advanced omics data analysis and interpretation.

Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS) , being held October 3-7, 2023 in Charleston, SC.

Today, Takeda Canada Inc. announced the launch of Clinical Trials (CT) Lexicon, an innovative app that provides healthcare professionals with a centralized library of key studies and data at their fingertips.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET.

Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced the completion of an entitlement offer to shareholders raising approximately $2.7 million before costs.

Ocean Biomedical, Inc. announced that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor mutations.

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the peer-reviewed journal Cancers, of the results of a clinical study on the utility of CTCs to detect disease relapse substantially earlier than what is currently possible with routine surveillance imaging, in patients with stage III melanoma.

STRM.BIO announced the continuation of their grant from the Bill & Melinda Gates Foundation to create novel technology platform capabilities for in vivo delivery of gene therapies being developed by the foundation.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) today announced that in vivo data highlighting the enhanced efficacy of Lantern’s drug candidate LP-184 in glioblastoma (GBM) were published in Clinical Cancer Research, a journal of the American Association for Cancer Research.